nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—melanoma	0.518	1	CbGaD
Clodronate—Myeloid leukaemia—Temozolomide—melanoma	0.0169	0.116	CcSEcCtD
Clodronate—SLC25A5—hair follicle—melanoma	0.0148	0.099	CbGeAlD
Clodronate—SLC25A4—hair follicle—melanoma	0.0139	0.0927	CbGeAlD
Clodronate—SLC25A6—neck—melanoma	0.0114	0.0763	CbGeAlD
Clodronate—SLC25A5—neck—melanoma	0.00995	0.0664	CbGeAlD
Clodronate—SLC25A6—eye—melanoma	0.00851	0.0568	CbGeAlD
Clodronate—SLC25A6—skin of body—melanoma	0.0074	0.0494	CbGeAlD
Clodronate—SLC25A5—eye—melanoma	0.0074	0.0494	CbGeAlD
Clodronate—Acute myeloid leukaemia—Docetaxel—melanoma	0.0072	0.0494	CcSEcCtD
Clodronate—SLC25A4—eye—melanoma	0.00694	0.0463	CbGeAlD
Clodronate—SLC25A4—retina—melanoma	0.00687	0.0459	CbGeAlD
Clodronate—SLC25A5—skin of body—melanoma	0.00644	0.043	CbGeAlD
Clodronate—Acute leukaemia—Carmustine—melanoma	0.00643	0.0441	CcSEcCtD
Clodronate—Acute leukaemia—Temozolomide—melanoma	0.00622	0.0426	CcSEcCtD
Clodronate—PTGS2—leg—melanoma	0.00614	0.041	CbGeAlD
Clodronate—SLC25A5—mammalian vulva—melanoma	0.00587	0.0392	CbGeAlD
Clodronate—PTGS2—hindlimb—melanoma	0.00548	0.0366	CbGeAlD
Clodronate—SLC25A6—head—melanoma	0.00483	0.0322	CbGeAlD
Clodronate—PTGS2—appendage—melanoma	0.00471	0.0314	CbGeAlD
Clodronate—SLC25A5—head—melanoma	0.0042	0.028	CbGeAlD
Clodronate—Acute leukaemia—Docetaxel—melanoma	0.00413	0.0284	CcSEcCtD
Clodronate—Neoplasm malignant—Vemurafenib—melanoma	0.00407	0.0279	CcSEcCtD
Clodronate—SLC25A4—head—melanoma	0.00394	0.0263	CbGeAlD
Clodronate—PTGS2—skin epidermis—melanoma	0.00391	0.0261	CbGeAlD
Clodronate—Local reaction—Bleomycin—melanoma	0.0038	0.0261	CcSEcCtD
Clodronate—SLC25A6—lymph node—melanoma	0.00338	0.0226	CbGeAlD
Clodronate—SLC25A5—lymph node—melanoma	0.00294	0.0196	CbGeAlD
Clodronate—PTGS2—endothelium—melanoma	0.00284	0.019	CbGeAlD
Clodronate—SLC25A4—lymph node—melanoma	0.00276	0.0184	CbGeAlD
Clodronate—Digestion impaired—Temozolomide—melanoma	0.00266	0.0182	CcSEcCtD
Clodronate—PTGS2—blood vessel—melanoma	0.00262	0.0175	CbGeAlD
Clodronate—Extravasation—Bleomycin—melanoma	0.00241	0.0166	CcSEcCtD
Clodronate—Extravasation—Dactinomycin—melanoma	0.00225	0.0154	CcSEcCtD
Clodronate—Hypocalcaemia—Dactinomycin—melanoma	0.00215	0.0147	CcSEcCtD
Clodronate—Extravasation—Carmustine—melanoma	0.00211	0.0145	CcSEcCtD
Clodronate—Foetor hepaticus—Docetaxel—melanoma	0.00208	0.0143	CcSEcCtD
Clodronate—Wheezing—Bleomycin—melanoma	0.00205	0.014	CcSEcCtD
Clodronate—Liver disorder—Docetaxel—melanoma	0.00173	0.0119	CcSEcCtD
Clodronate—Connective tissue disorder—Vemurafenib—melanoma	0.00172	0.0118	CcSEcCtD
Clodronate—Mediastinal disorder—Vemurafenib—melanoma	0.00157	0.0108	CcSEcCtD
Clodronate—Extravasation—Docetaxel—melanoma	0.00135	0.00929	CcSEcCtD
Clodronate—Bronchospasm—Bleomycin—melanoma	0.0013	0.00892	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00128	0.00881	CcSEcCtD
Clodronate—Oliguria—Docetaxel—melanoma	0.00128	0.00879	CcSEcCtD
Clodronate—Dysphagia—Dactinomycin—melanoma	0.00123	0.00845	CcSEcCtD
Clodronate—Infection—Vemurafenib—melanoma	0.00123	0.00845	CcSEcCtD
Clodronate—PTGS2—skin of body—melanoma	0.00121	0.00809	CbGeAlD
Clodronate—Skin disorder—Vemurafenib—melanoma	0.0012	0.00826	CcSEcCtD
Clodronate—Dehydration—Temozolomide—melanoma	0.0012	0.00823	CcSEcCtD
Clodronate—Pneumonia—Bleomycin—melanoma	0.00118	0.00813	CcSEcCtD
Clodronate—Hepatocellular injury—Docetaxel—melanoma	0.00118	0.00811	CcSEcCtD
Clodronate—Dysphagia—Carmustine—melanoma	0.00115	0.00791	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Temozolomide—melanoma	0.00114	0.0078	CcSEcCtD
Clodronate—Dysphagia—Temozolomide—melanoma	0.00111	0.00765	CcSEcCtD
Clodronate—Pneumonia—Dactinomycin—melanoma	0.00111	0.00758	CcSEcCtD
Clodronate—Decreased appetite—Vemurafenib—melanoma	0.00108	0.0074	CcSEcCtD
Clodronate—Gastrointestinal disorder—Vemurafenib—melanoma	0.00107	0.00735	CcSEcCtD
Clodronate—Pneumonia—Carmustine—melanoma	0.00103	0.0071	CcSEcCtD
Clodronate—Renal failure—Carmustine—melanoma	0.00101	0.00693	CcSEcCtD
Clodronate—Pneumonia—Temozolomide—melanoma	0.001	0.00686	CcSEcCtD
Clodronate—Pharyngitis—Dactinomycin—melanoma	0.000979	0.00672	CcSEcCtD
Clodronate—Connective tissue disorder—Carmustine—melanoma	0.000907	0.00622	CcSEcCtD
Clodronate—Renal impairment—Docetaxel—melanoma	0.000901	0.00618	CcSEcCtD
Clodronate—Pharyngitis—Temozolomide—melanoma	0.000885	0.00607	CcSEcCtD
Clodronate—Urinary tract disorder—Temozolomide—melanoma	0.000881	0.00604	CcSEcCtD
Clodronate—Cardiac failure—Docetaxel—melanoma	0.000879	0.00603	CcSEcCtD
Clodronate—Pruritus—Vemurafenib—melanoma	0.000877	0.00602	CcSEcCtD
Clodronate—Connective tissue disorder—Temozolomide—melanoma	0.000877	0.00601	CcSEcCtD
Clodronate—Urethral disorder—Temozolomide—melanoma	0.000874	0.006	CcSEcCtD
Clodronate—Anaemia—Bleomycin—melanoma	0.000851	0.00584	CcSEcCtD
Clodronate—Diarrhoea—Vemurafenib—melanoma	0.000849	0.00582	CcSEcCtD
Clodronate—Mediastinal disorder—Temozolomide—melanoma	0.000804	0.00552	CcSEcCtD
Clodronate—Dehydration—Docetaxel—melanoma	0.000798	0.00547	CcSEcCtD
Clodronate—Anaemia—Dactinomycin—melanoma	0.000794	0.00544	CcSEcCtD
Clodronate—PTGS2—head—melanoma	0.000791	0.00528	CbGeAlD
Clodronate—Vomiting—Vemurafenib—melanoma	0.000789	0.00541	CcSEcCtD
Clodronate—Abdominal pain upper—Docetaxel—melanoma	0.000783	0.00537	CcSEcCtD
Clodronate—Rash—Vemurafenib—melanoma	0.000782	0.00536	CcSEcCtD
Clodronate—Dermatitis—Vemurafenib—melanoma	0.000781	0.00536	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Docetaxel—melanoma	0.000756	0.00519	CcSEcCtD
Clodronate—Infection—Bleomycin—melanoma	0.000746	0.00512	CcSEcCtD
Clodronate—Anaemia—Carmustine—melanoma	0.000743	0.0051	CcSEcCtD
Clodronate—Dysphagia—Docetaxel—melanoma	0.000741	0.00508	CcSEcCtD
Clodronate—Nausea—Vemurafenib—melanoma	0.000737	0.00505	CcSEcCtD
Clodronate—Bronchospasm—Docetaxel—melanoma	0.000729	0.005	CcSEcCtD
Clodronate—Anaemia—Temozolomide—melanoma	0.000718	0.00492	CcSEcCtD
Clodronate—Anorexia—Bleomycin—melanoma	0.000716	0.00491	CcSEcCtD
Clodronate—Angioedema—Temozolomide—melanoma	0.00071	0.00487	CcSEcCtD
Clodronate—Infection—Dactinomycin—melanoma	0.000696	0.00478	CcSEcCtD
Clodronate—Dyspnoea—Bleomycin—melanoma	0.00067	0.0046	CcSEcCtD
Clodronate—Anorexia—Dactinomycin—melanoma	0.000668	0.00458	CcSEcCtD
Clodronate—Pneumonia—Docetaxel—melanoma	0.000665	0.00456	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000657	0.0045	CcSEcCtD
Clodronate—Decreased appetite—Bleomycin—melanoma	0.000653	0.00448	CcSEcCtD
Clodronate—Infection—Carmustine—melanoma	0.000652	0.00447	CcSEcCtD
Clodronate—Renal failure—Docetaxel—melanoma	0.00065	0.00446	CcSEcCtD
Clodronate—Infection—Temozolomide—melanoma	0.00063	0.00432	CcSEcCtD
Clodronate—Anorexia—Carmustine—melanoma	0.000625	0.00429	CcSEcCtD
Clodronate—Skin disorder—Temozolomide—melanoma	0.000616	0.00422	CcSEcCtD
Clodronate—Decreased appetite—Dactinomycin—melanoma	0.000609	0.00418	CcSEcCtD
Clodronate—Anorexia—Temozolomide—melanoma	0.000604	0.00414	CcSEcCtD
Clodronate—Urticaria—Bleomycin—melanoma	0.000597	0.0041	CcSEcCtD
Clodronate—Pharyngitis—Docetaxel—melanoma	0.000589	0.00404	CcSEcCtD
Clodronate—Urinary tract disorder—Docetaxel—melanoma	0.000586	0.00402	CcSEcCtD
Clodronate—Dyspnoea—Carmustine—melanoma	0.000585	0.00401	CcSEcCtD
Clodronate—Connective tissue disorder—Docetaxel—melanoma	0.000583	0.004	CcSEcCtD
Clodronate—Urethral disorder—Docetaxel—melanoma	0.000582	0.00399	CcSEcCtD
Clodronate—Decreased appetite—Carmustine—melanoma	0.00057	0.00391	CcSEcCtD
Clodronate—Gastrointestinal disorder—Carmustine—melanoma	0.000566	0.00388	CcSEcCtD
Clodronate—Dyspnoea—Temozolomide—melanoma	0.000565	0.00388	CcSEcCtD
Clodronate—Dyspepsia—Temozolomide—melanoma	0.000558	0.00383	CcSEcCtD
Clodronate—PTGS2—lymph node—melanoma	0.000554	0.0037	CbGeAlD
Clodronate—Abdominal pain—Dactinomycin—melanoma	0.000554	0.0038	CcSEcCtD
Clodronate—Decreased appetite—Temozolomide—melanoma	0.000551	0.00378	CcSEcCtD
Clodronate—Gastrointestinal disorder—Temozolomide—melanoma	0.000547	0.00375	CcSEcCtD
Clodronate—Mediastinal disorder—Docetaxel—melanoma	0.000535	0.00367	CcSEcCtD
Clodronate—Pruritus—Bleomycin—melanoma	0.000532	0.00365	CcSEcCtD
Clodronate—Abdominal pain—Carmustine—melanoma	0.000518	0.00356	CcSEcCtD
Clodronate—Urticaria—Temozolomide—melanoma	0.000504	0.00345	CcSEcCtD
Clodronate—Abdominal pain—Temozolomide—melanoma	0.000501	0.00344	CcSEcCtD
Clodronate—Diarrhoea—Dactinomycin—melanoma	0.000479	0.00329	CcSEcCtD
Clodronate—Vomiting—Bleomycin—melanoma	0.000478	0.00328	CcSEcCtD
Clodronate—Anaemia—Docetaxel—melanoma	0.000477	0.00327	CcSEcCtD
Clodronate—Rash—Bleomycin—melanoma	0.000474	0.00325	CcSEcCtD
Clodronate—Dermatitis—Bleomycin—melanoma	0.000473	0.00325	CcSEcCtD
Clodronate—Diarrhoea—Carmustine—melanoma	0.000449	0.00308	CcSEcCtD
Clodronate—Pruritus—Temozolomide—melanoma	0.000448	0.00308	CcSEcCtD
Clodronate—Nausea—Bleomycin—melanoma	0.000446	0.00306	CcSEcCtD
Clodronate—Vomiting—Dactinomycin—melanoma	0.000446	0.00306	CcSEcCtD
Clodronate—Rash—Dactinomycin—melanoma	0.000442	0.00303	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000437	0.003	CcSEcCtD
Clodronate—Diarrhoea—Temozolomide—melanoma	0.000434	0.00298	CcSEcCtD
Clodronate—Infection—Docetaxel—melanoma	0.000419	0.00287	CcSEcCtD
Clodronate—Vomiting—Carmustine—melanoma	0.000417	0.00286	CcSEcCtD
Clodronate—Nausea—Dactinomycin—melanoma	0.000416	0.00286	CcSEcCtD
Clodronate—Rash—Carmustine—melanoma	0.000414	0.00284	CcSEcCtD
Clodronate—Dermatitis—Carmustine—melanoma	0.000413	0.00283	CcSEcCtD
Clodronate—Skin disorder—Docetaxel—melanoma	0.000409	0.00281	CcSEcCtD
Clodronate—Vomiting—Temozolomide—melanoma	0.000403	0.00276	CcSEcCtD
Clodronate—Anorexia—Docetaxel—melanoma	0.000402	0.00276	CcSEcCtD
Clodronate—Rash—Temozolomide—melanoma	0.0004	0.00274	CcSEcCtD
Clodronate—Dermatitis—Temozolomide—melanoma	0.000399	0.00274	CcSEcCtD
Clodronate—Nausea—Carmustine—melanoma	0.00039	0.00267	CcSEcCtD
Clodronate—Nausea—Temozolomide—melanoma	0.000376	0.00258	CcSEcCtD
Clodronate—Dyspnoea—Docetaxel—melanoma	0.000376	0.00258	CcSEcCtD
Clodronate—Dyspepsia—Docetaxel—melanoma	0.000371	0.00255	CcSEcCtD
Clodronate—Decreased appetite—Docetaxel—melanoma	0.000366	0.00251	CcSEcCtD
Clodronate—Gastrointestinal disorder—Docetaxel—melanoma	0.000364	0.0025	CcSEcCtD
Clodronate—Abdominal pain—Docetaxel—melanoma	0.000333	0.00229	CcSEcCtD
Clodronate—Pruritus—Docetaxel—melanoma	0.000298	0.00205	CcSEcCtD
Clodronate—Diarrhoea—Docetaxel—melanoma	0.000288	0.00198	CcSEcCtD
Clodronate—Vomiting—Docetaxel—melanoma	0.000268	0.00184	CcSEcCtD
Clodronate—Rash—Docetaxel—melanoma	0.000266	0.00182	CcSEcCtD
Clodronate—Dermatitis—Docetaxel—melanoma	0.000266	0.00182	CcSEcCtD
Clodronate—Nausea—Docetaxel—melanoma	0.00025	0.00172	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—melanoma	0.000101	0.000542	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—NFKB1—melanoma	0.000101	0.00054	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ACER3—melanoma	0.0001	0.000538	CbGpPWpGaD
Clodronate—SLC25A6—Disease—FGF2—melanoma	9.95e-05	0.000534	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—melanoma	9.92e-05	0.000532	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CG—melanoma	9.9e-05	0.000531	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PRKCA—melanoma	9.87e-05	0.000529	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ERCC2—melanoma	9.79e-05	0.000525	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—RAC1—melanoma	9.73e-05	0.000522	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CTNNB1—melanoma	9.59e-05	0.000514	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IFNG—melanoma	9.57e-05	0.000513	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PPARG—melanoma	9.56e-05	0.000512	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NOS2—melanoma	9.53e-05	0.000511	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NOTCH1—melanoma	9.44e-05	0.000506	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—NRAS—melanoma	9.37e-05	0.000502	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDKN1A—melanoma	9.36e-05	0.000502	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTEN—melanoma	9.34e-05	0.000501	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MDM2—melanoma	9.31e-05	0.000499	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD80—melanoma	9.25e-05	0.000496	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK2—melanoma	9.24e-05	0.000495	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KIT—melanoma	9.23e-05	0.000495	CbGpPWpGaD
Clodronate—SLC25A4—Disease—APC—melanoma	9.23e-05	0.000495	CbGpPWpGaD
Clodronate—SLC25A6—Disease—ERBB2—melanoma	9.18e-05	0.000492	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—UGT2B10—melanoma	9.18e-05	0.000492	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGF—melanoma	9.13e-05	0.000489	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	9.06e-05	0.000486	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CB—melanoma	9.06e-05	0.000486	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CB—melanoma	9.06e-05	0.000485	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CD4—melanoma	9.04e-05	0.000485	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTGS2—melanoma	8.98e-05	0.000481	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS2—melanoma	8.97e-05	0.000481	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CXCL8—melanoma	8.9e-05	0.000477	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—melanoma	8.77e-05	0.00047	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—melanoma	8.73e-05	0.000468	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYC—melanoma	8.73e-05	0.000468	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CD—melanoma	8.71e-05	0.000467	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CDKN1B—melanoma	8.69e-05	0.000466	CbGpPWpGaD
Clodronate—SLC25A4—Disease—BRAF—melanoma	8.68e-05	0.000465	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ALB—melanoma	8.59e-05	0.000461	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HS3ST5—melanoma	8.53e-05	0.000458	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CASP3—melanoma	8.52e-05	0.000457	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN1B—melanoma	8.5e-05	0.000456	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—melanoma	8.5e-05	0.000456	CbGpPWpGaD
Clodronate—SLC25A5—Disease—STAT3—melanoma	8.36e-05	0.000448	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NRAS—melanoma	8.34e-05	0.000447	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCND1—melanoma	8.29e-05	0.000444	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—melanoma	8.22e-05	0.000441	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAP2K1—melanoma	8.17e-05	0.000438	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—melanoma	8.12e-05	0.000436	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CD—melanoma	8.12e-05	0.000435	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—melanoma	8.06e-05	0.000432	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MMP9—melanoma	8.05e-05	0.000431	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CTNNB1—melanoma	8.03e-05	0.000431	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MAPK3—melanoma	7.98e-05	0.000428	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN1A—melanoma	7.85e-05	0.000421	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—TNF—melanoma	7.83e-05	0.00042	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTEN—melanoma	7.83e-05	0.00042	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTEN—melanoma	7.83e-05	0.00042	CbGpPWpGaD
Clodronate—SLC25A4—Disease—FGF2—melanoma	7.77e-05	0.000417	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MYC—melanoma	7.76e-05	0.000416	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CG—melanoma	7.73e-05	0.000414	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	7.66e-05	0.00041	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MAPK1—melanoma	7.6e-05	0.000407	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EGFR—melanoma	7.59e-05	0.000407	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CB—melanoma	7.59e-05	0.000407	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	7.53e-05	0.000403	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS2—melanoma	7.52e-05	0.000403	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PPARG—melanoma	7.46e-05	0.0004	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	7.27e-05	0.00039	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MDM2—melanoma	7.27e-05	0.00039	CbGpPWpGaD
Clodronate—PTGS2—Disease—TRRAP—melanoma	7.26e-05	0.000389	CbGpPWpGaD
Clodronate—PTGS2—Disease—CUL3—melanoma	7.26e-05	0.000389	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—melanoma	7.17e-05	0.000385	CbGpPWpGaD
Clodronate—SLC25A4—Disease—ERBB2—melanoma	7.17e-05	0.000384	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CB—melanoma	7.07e-05	0.000379	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKR1B10—melanoma	7.06e-05	0.000379	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD4—melanoma	7.06e-05	0.000379	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTGS2—melanoma	7.01e-05	0.000376	CbGpPWpGaD
Clodronate—SLC25A6—Disease—STAT3—melanoma	7e-05	0.000375	CbGpPWpGaD
Clodronate—SLC25A6—Disease—NRAS—melanoma	6.99e-05	0.000375	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	6.92e-05	0.000371	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	6.87e-05	0.000368	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—HRAS—melanoma	6.85e-05	0.000367	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MAPK3—melanoma	6.84e-05	0.000366	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CD—melanoma	6.8e-05	0.000364	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ALB—melanoma	6.71e-05	0.00036	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MAPK3—melanoma	6.69e-05	0.000359	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—melanoma	6.65e-05	0.000356	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1B—melanoma	6.64e-05	0.000356	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PIK3CA—melanoma	6.59e-05	0.000353	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	6.57e-05	0.000352	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTEN—melanoma	6.56e-05	0.000352	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—melanoma	6.51e-05	0.000349	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MAPK1—melanoma	6.5e-05	0.000349	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGFR—melanoma	6.5e-05	0.000349	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	6.47e-05	0.000347	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PLCB4—melanoma	6.47e-05	0.000347	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	6.38e-05	0.000342	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MAPK1—melanoma	6.37e-05	0.000341	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EGFR—melanoma	6.36e-05	0.000341	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—FASN—melanoma	6.35e-05	0.00034	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IL6—melanoma	6.32e-05	0.000339	CbGpPWpGaD
Clodronate—PTGS2—Disease—LUM—melanoma	6.3e-05	0.000338	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CTNNB1—melanoma	6.27e-05	0.000336	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TNF—melanoma	6.19e-05	0.000332	CbGpPWpGaD
Clodronate—PTGS2—Disease—HPSE—melanoma	6.17e-05	0.000331	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1A—melanoma	6.13e-05	0.000328	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTEN—melanoma	6.11e-05	0.000328	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HRAS—melanoma	6.1e-05	0.000327	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC6A11—melanoma	6.08e-05	0.000326	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIP4K2A—melanoma	6.08e-05	0.000326	CbGpPWpGaD
Clodronate—PTGS2—Disease—CUBN—melanoma	6.06e-05	0.000325	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—melanoma	6.01e-05	0.000322	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CB—melanoma	5.92e-05	0.000318	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MTAP—melanoma	5.92e-05	0.000317	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	5.91e-05	0.000317	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS2—melanoma	5.87e-05	0.000315	CbGpPWpGaD
Clodronate—PTGS2—Disease—CSPG4—melanoma	5.85e-05	0.000314	CbGpPWpGaD
Clodronate—SLC25A5—Disease—IL6—melanoma	5.84e-05	0.000313	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	5.79e-05	0.000311	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	5.78e-05	0.00031	CbGpPWpGaD
Clodronate—PTGS2—Disease—RPS3—melanoma	5.76e-05	0.000309	CbGpPWpGaD
Clodronate—PTGS2—Disease—SKI—melanoma	5.67e-05	0.000304	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	5.64e-05	0.000302	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	5.58e-05	0.000299	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CA—melanoma	5.52e-05	0.000296	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CA—melanoma	5.52e-05	0.000296	CbGpPWpGaD
Clodronate—SLC25A4—Disease—STAT3—melanoma	5.47e-05	0.000293	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—melanoma	5.46e-05	0.000293	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	5.45e-05	0.000292	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NRAS—melanoma	5.45e-05	0.000292	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	5.44e-05	0.000292	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	5.42e-05	0.00029	CbGpPWpGaD
Clodronate—SLC25A5—Disease—AKT1—melanoma	5.38e-05	0.000289	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PHGDH—melanoma	5.27e-05	0.000283	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—LUM—melanoma	5.27e-05	0.000283	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAPK3—melanoma	5.22e-05	0.00028	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HPSE—melanoma	5.17e-05	0.000277	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTEN—melanoma	5.12e-05	0.000274	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HRAS—melanoma	5.11e-05	0.000274	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—melanoma	5.08e-05	0.000272	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CUBN—melanoma	5.08e-05	0.000272	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL6—melanoma	5e-05	0.000268	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAPK1—melanoma	4.97e-05	0.000266	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGFR—melanoma	4.97e-05	0.000266	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	4.92e-05	0.000264	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SDHD—melanoma	4.9e-05	0.000263	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CSPG4—melanoma	4.9e-05	0.000263	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—BSG—melanoma	4.9e-05	0.000263	CbGpPWpGaD
Clodronate—SLC25A6—Disease—IL6—melanoma	4.89e-05	0.000262	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GPAM—melanoma	4.75e-05	0.000255	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—melanoma	4.69e-05	0.000252	CbGpPWpGaD
Clodronate—PTGS2—Disease—HDAC6—melanoma	4.68e-05	0.000251	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	4.65e-05	0.000249	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CA—melanoma	4.63e-05	0.000248	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—melanoma	4.52e-05	0.000242	CbGpPWpGaD
Clodronate—SLC25A6—Disease—AKT1—melanoma	4.51e-05	0.000242	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKT1—melanoma	4.51e-05	0.000242	CbGpPWpGaD
Clodronate—PTGS2—Disease—NPPA—melanoma	4.44e-05	0.000238	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	4.42e-05	0.000237	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	4.42e-05	0.000237	CbGpPWpGaD
Clodronate—PTGS2—Disease—VCAN—melanoma	4.33e-05	0.000232	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CA—melanoma	4.31e-05	0.000231	CbGpPWpGaD
Clodronate—PTGS2—Disease—WNT5A—melanoma	4.3e-05	0.00023	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—melanoma	4.21e-05	0.000226	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	4.18e-05	0.000224	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PLA2G6—melanoma	4.04e-05	0.000216	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HRAS—melanoma	3.99e-05	0.000214	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	3.84e-05	0.000206	CbGpPWpGaD
Clodronate—SLC25A4—Disease—IL6—melanoma	3.82e-05	0.000205	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—AKT1—melanoma	3.78e-05	0.000203	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—melanoma	3.71e-05	0.000199	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—VCAN—melanoma	3.63e-05	0.000194	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CA—melanoma	3.61e-05	0.000194	CbGpPWpGaD
Clodronate—SLC25A4—Disease—AKT1—melanoma	3.52e-05	0.000189	CbGpPWpGaD
Clodronate—PTGS2—Disease—GAB2—melanoma	3.45e-05	0.000185	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	3.43e-05	0.000184	CbGpPWpGaD
Clodronate—PTGS2—Disease—FASN—melanoma	3.38e-05	0.000181	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—melanoma	3.31e-05	0.000178	CbGpPWpGaD
Clodronate—PTGS2—Disease—FOXO4—melanoma	3.24e-05	0.000174	CbGpPWpGaD
Clodronate—PTGS2—Disease—HDAC2—melanoma	3.24e-05	0.000174	CbGpPWpGaD
Clodronate—PTGS2—Disease—CXCR4—melanoma	3.24e-05	0.000174	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD44—melanoma	3.21e-05	0.000172	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	3.14e-05	0.000168	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP17A1—melanoma	3.06e-05	0.000164	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	3.02e-05	0.000162	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—ALB—melanoma	2.98e-05	0.00016	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKT3—melanoma	2.96e-05	0.000159	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—AKT1—melanoma	2.95e-05	0.000158	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GNA11—melanoma	2.89e-05	0.000155	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—FASN—melanoma	2.83e-05	0.000152	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC5A5—melanoma	2.78e-05	0.000149	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GNAQ—melanoma	2.69e-05	0.000144	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CD44—melanoma	2.69e-05	0.000144	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.63e-05	0.000141	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB4—melanoma	2.61e-05	0.00014	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN2B—melanoma	2.59e-05	0.000139	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP1B1—melanoma	2.57e-05	0.000138	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD86—melanoma	2.51e-05	0.000134	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGF1—melanoma	2.43e-05	0.00013	CbGpPWpGaD
Clodronate—PTGS2—Disease—PDGFRA—melanoma	2.35e-05	0.000126	CbGpPWpGaD
Clodronate—PTGS2—Disease—PRKCA—melanoma	2.33e-05	0.000125	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERCC2—melanoma	2.31e-05	0.000124	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAP2K2—melanoma	2.28e-05	0.000122	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.27e-05	0.000122	CbGpPWpGaD
Clodronate—PTGS2—Disease—TERT—melanoma	2.17e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Disease—HLA-A—melanoma	2.17e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Disease—RAC1—melanoma	2.16e-05	0.000116	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ABCB1—melanoma	2.12e-05	0.000114	CbGpPWpGaD
Clodronate—PTGS2—Disease—HIF1A—melanoma	2.07e-05	0.000111	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PRKCA—melanoma	1.95e-05	0.000105	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ERCC2—melanoma	1.94e-05	0.000104	CbGpPWpGaD
Clodronate—PTGS2—Disease—NOS2—melanoma	1.88e-05	0.000101	CbGpPWpGaD
Clodronate—PTGS2—Disease—NOTCH1—melanoma	1.87e-05	0.0001	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD80—melanoma	1.83e-05	9.8e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—KIT—melanoma	1.83e-05	9.78e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—APC—melanoma	1.83e-05	9.78e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGF—melanoma	1.8e-05	9.67e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—BRAF—melanoma	1.72e-05	9.2e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAP2K1—melanoma	1.62e-05	8.66e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CD—melanoma	1.6e-05	8.6e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.6e-05	8.59e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGF2—melanoma	1.54e-05	8.24e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CG—melanoma	1.53e-05	8.19e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPARG—melanoma	1.48e-05	7.91e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MDM2—melanoma	1.44e-05	7.71e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB2—melanoma	1.42e-05	7.6e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CB—melanoma	1.4e-05	7.5e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD4—melanoma	1.4e-05	7.48e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CD—melanoma	1.34e-05	7.2e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ALB—melanoma	1.33e-05	7.11e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1B—melanoma	1.31e-05	7.04e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CTNNB1—melanoma	1.24e-05	6.65e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1A—melanoma	1.21e-05	6.49e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PTEN—melanoma	1.21e-05	6.48e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CB—melanoma	1.17e-05	6.28e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—STAT3—melanoma	1.08e-05	5.79e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—NRAS—melanoma	1.08e-05	5.78e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAPK3—melanoma	1.03e-05	5.54e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTEN—melanoma	1.01e-05	5.43e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—melanoma	1e-05	5.38e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAPK1—melanoma	9.83e-06	5.27e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGFR—melanoma	9.82e-06	5.27e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—melanoma	9.28e-06	4.97e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CA—melanoma	8.53e-06	4.57e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—HRAS—melanoma	7.89e-06	4.23e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—IL6—melanoma	7.55e-06	4.05e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CA—melanoma	7.14e-06	3.83e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKT1—melanoma	6.96e-06	3.73e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKT1—melanoma	5.83e-06	3.13e-05	CbGpPWpGaD
